[{"orgOrder":0,"company":"Foundation for Orthopaedic Research and Education","sponsor":"Pacira BioSciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Foundation for Orthopaedic Research and Education","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Foundation for Orthopaedic Research and Education \/ Pacira BioSciences","highestDevelopmentStatusID":"9","companyTruncated":"Foundation for Orthopaedic Research and Education \/ Pacira BioSciences"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Depuy Synthes Sales","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Termination","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pacira BioSciences \/ Depuy Synthes Sales","highestDevelopmentStatusID":"15","companyTruncated":"Pacira BioSciences \/ Depuy Synthes Sales"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Premier","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Agreement","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pacira BioSciences \/ Premier","highestDevelopmentStatusID":"15","companyTruncated":"Pacira BioSciences \/ Premier"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pacira BioSciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pacira BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Eurofarma Laboratorios S.A","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pacira BioSciences \/ Eurofarma Laboratorios S.A","highestDevelopmentStatusID":"15","companyTruncated":"Pacira BioSciences \/ Eurofarma Laboratorios S.A"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pacira BioSciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pacira BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection, Suspension, Prolonged Release","sponsorNew":"Pacira BioSciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pacira BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection, Suspension, Prolonged Release","sponsorNew":"Pacira BioSciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pacira BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Podiatry","graph2":"Phase III","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Pacira BioSciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pacira BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension, Liposomal","sponsorNew":"Pacira BioSciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pacira BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pacira BioSciences \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pacira BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Nang Kuang Pharmaceutical Co. Ltd.","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"TAIWAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Phase I","graph3":"Nang Kuang Pharmaceutical Co. Ltd.","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Nang Kuang Pharmaceutical Co. Ltd. \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Nang Kuang Pharmaceutical Co. Ltd. \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CHINA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Phase II","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Zuyderland Medisch Centrum","sponsor":"AtriCure","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"NETHERLANDS","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Zuyderland Medisch Centrum","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zuyderland Medisch Centrum \/ AtriCure","highestDevelopmentStatusID":"1","companyTruncated":"Zuyderland Medisch Centrum \/ AtriCure"},{"orgOrder":0,"company":"Evonik","sponsor":"Allay Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"GERMANY","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Phase II","graph3":"Evonik","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Evonik \/ Allay Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Evonik \/ Allay Therapeutics"},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"APIM Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Miscellaneous","year":"2022","type":"Merger","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Oncology","graph2":"Phase II","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nordic Nanovector \/ APIM Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Nordic Nanovector \/ APIM Therapeutics"},{"orgOrder":0,"company":"OncoZenge","sponsor":"Baltic Sea Foundation","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Miscellaneous","year":"2020","type":"Financing","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Phase II","graph3":"OncoZenge","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"OncoZenge \/ Baltic Sea Foundation","highestDevelopmentStatusID":"8","companyTruncated":"OncoZenge \/ Baltic Sea Foundation"},{"orgOrder":0,"company":"University of California, San Diego","sponsor":"Pacira BioSciences","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Undisclosed","graph2":"Phase IV","graph3":"University of California, San Diego","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, San Diego \/ Pacira BioSciences","highestDevelopmentStatusID":"11","companyTruncated":"University of California, San Diego \/ Pacira BioSciences"},{"orgOrder":0,"company":"Yale University","sponsor":"VA Connecticut Healthcare System | National Headache Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Phase I","graph3":"Yale University","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Yale University \/ VA Connecticut Healthcare System | National Headache Foundation","highestDevelopmentStatusID":"6","companyTruncated":"Yale University \/ VA Connecticut Healthcare System | National Headache Foundation"},{"orgOrder":0,"company":"University of Calgary","sponsor":"Alberta Health services | Alberta Hip and Knee Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"University of Calgary","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Calgary \/ Alberta Health services | Alberta Hip and Knee Clinic","highestDevelopmentStatusID":"11","companyTruncated":"University of Calgary \/ Alberta Health services | Alberta Hip and Knee Clinic"},{"orgOrder":0,"company":"St. Joseph's Healthcare Hamilton","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"CANADA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Phase II","graph3":"St. Joseph's Healthcare Hamilton","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"St. Joseph's Healthcare Hamilton \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"St. Joseph's Healthcare Hamilton \/ Undisclosed"},{"orgOrder":0,"company":"Fraser Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Undisclosed","graph3":"Fraser Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fraser Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Fraser Health \/ Undisclosed"},{"orgOrder":0,"company":"Baptist Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Phase IV","graph3":"Baptist Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Baptist Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Baptist Health \/ Undisclosed"},{"orgOrder":0,"company":"Northern Light Mercy Hospital","sponsor":"MaineHealth","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase IV","graph3":"Northern Light Mercy Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Northern Light Mercy Hospital \/ MaineHealth","highestDevelopmentStatusID":"11","companyTruncated":"Northern Light Mercy Hospital \/ MaineHealth"},{"orgOrder":0,"company":"Rutgers, The State University of New Jersey","sponsor":"Pacira BioSciences","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Rutgers, The State University of New Jersey","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Rutgers, The State University of New Jersey \/ Pacira BioSciences","highestDevelopmentStatusID":"9","companyTruncated":"Rutgers, The State University of New Jersey \/ Pacira BioSciences"},{"orgOrder":0,"company":"MediSys Health Network","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Undisclosed","graph2":"Phase IV","graph3":"MediSys Health Network","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"MediSys Health Network \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"MediSys Health Network \/ Undisclosed"},{"orgOrder":0,"company":"Northwell Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Phase IV","graph3":"Northwell Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Northwell Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Northwell Health \/ Undisclosed"},{"orgOrder":0,"company":"TriHealth","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Urology","graph2":"Phase IV","graph3":"TriHealth","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Solution","sponsorNew":"TriHealth \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"TriHealth \/ Undisclosed"},{"orgOrder":0,"company":"Samaritan Health Services","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Oncology","graph2":"Phase IV","graph3":"Samaritan Health Services","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Samaritan Health Services \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Samaritan Health Services \/ Undisclosed"},{"orgOrder":0,"company":"University of Tennessee","sponsor":"Regional One Health","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Phase IV","graph3":"University of Tennessee","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"University of Tennessee \/ Regional One Health","highestDevelopmentStatusID":"11","companyTruncated":"University of Tennessee \/ Regional One Health"},{"orgOrder":0,"company":"Allay Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Phase II","graph3":"Allay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Allay Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allay Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allay Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Phase II","graph3":"Allay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Allay Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allay Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allay Therapeutics","sponsor":"Arboretum Ventures","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Series C Financing","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Allay Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0.059999999999999998,"dosageForm":"Implant","sponsorNew":"Allay Therapeutics \/ Arboretum Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Allay Therapeutics \/ Arboretum Ventures"},{"orgOrder":0,"company":"Allay Therapeutics","sponsor":"Maruishi Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Allay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Allay Therapeutics \/ Maruishi Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"Allay Therapeutics \/ Maruishi Pharmaceutical"},{"orgOrder":0,"company":"Allay Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Phase II","graph3":"Allay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Allay Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allay Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Allay Therapeutics","sponsor":"Lightstone Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Series D Financing","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Phase II","graph3":"Allay Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.059999999999999998,"dosageForm":"Implant","sponsorNew":"Allay Therapeutics \/ Lightstone Ventures","highestDevelopmentStatusID":"8","companyTruncated":"Allay Therapeutics \/ Lightstone Ventures"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pacira BioSciences \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pacira BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Preclinical","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Virpax Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Virpax Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Preclinical","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Virpax Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Virpax Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Allay Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Phase II","graph3":"Allay Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Allay Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Allay Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Preclinical","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Virpax Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Virpax Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Preclinical","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Virpax Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Virpax Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Preclinical","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Virpax Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Virpax Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Preclinical","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Virpax Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Virpax Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Preclinical","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Virpax Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Virpax Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Virpax Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Preclinical","graph3":"Virpax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Virpax Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Virpax Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Orthopedics\/Orthopedic Surgery","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"||Sodium channel protein type IV alpha subunit","graph1":"Orthopedics\/Orthopedic Surgery","graph2":"Phase II","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Orthopedics","amount2New":0,"dosageForm":"Solution, Extended Release","sponsorNew":"Heron Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Heron Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Durect Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Durect Corporation","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution, Extended Release","sponsorNew":"Durect Corporation \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Durect Corporation \/ Undisclosed"},{"orgOrder":0,"company":"CrossLink Life Sciences","sponsor":"Heron Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Partnership","leadProduct":"Bupivacaine","moa":"||Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"CrossLink Life Sciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection, Solution, Extended Release","sponsorNew":"CrossLink Life Sciences \/ Heron Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"CrossLink Life Sciences \/ Heron Therapeutics"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"||Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection, Solution, Extended Release","sponsorNew":"Heron Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Heron Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Mayo Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"||Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection, Solution, Extended Release","sponsorNew":"Heron Therapeutics \/ Mayo Clinic","highestDevelopmentStatusID":"15","companyTruncated":"Heron Therapeutics \/ Mayo Clinic"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"||Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection, Solution, Extended Release","sponsorNew":"Heron Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Heron Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"||Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection, Solution, Extended Release","sponsorNew":"Heron Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Heron Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"||Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection, Solution, Extended Release","sponsorNew":"Heron Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Heron Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"||Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection, Solution, Extended Release","sponsorNew":"Heron Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Heron Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"||Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection, Solution, Extended Release","sponsorNew":"Heron Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Heron Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"||Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection, Solution, Extended Release","sponsorNew":"Heron Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Heron Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"||Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection, Solution, Extended Release","sponsorNew":"Heron Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Heron Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"||Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection, Solution, Extended Release","sponsorNew":"Heron Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Heron Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"J. Wood Capital Advisors","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Financing","leadProduct":"Bupivacaine","moa":"||Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Heron Therapeutics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0.14999999999999999,"dosageForm":"Injection, Solution, Extended Release","sponsorNew":"Heron Therapeutics \/ J. Wood Capital Advisors","highestDevelopmentStatusID":"15","companyTruncated":"Heron Therapeutics \/ J. Wood Capital Advisors"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Mayo Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"||Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection, Solution, Extended Release","sponsorNew":"Heron Therapeutics \/ Mayo Clinic","highestDevelopmentStatusID":"15","companyTruncated":"Heron Therapeutics \/ Mayo Clinic"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"||Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection, Solution, Extended Release","sponsorNew":"Heron Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Heron Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"||Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection, Solution, Extended Release","sponsorNew":"Heron Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Heron Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"||Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection, Solution, Extended Release","sponsorNew":"Heron Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Heron Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Heron Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"||Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Approved FDF","graph3":"Heron Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection, Solution, Extended Release","sponsorNew":"Heron Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Heron Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Pacira BioSciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pacira BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Podiatry","graph2":"Phase III","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Pacira BioSciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Pacira BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"Pacira BioSciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Pacira BioSciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Pacira BioSciences \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Pacira BioSciences \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Psychiatry\/Psychology","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Hamilton Health Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Oncology","graph2":"Phase IV","graph3":"Hamilton Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hamilton Health Sciences \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Hamilton Health Sciences \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Phase IV","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Rebel Medicine","sponsor":"Crocker Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Series A Financing","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"IND Enabling","graph3":"Rebel Medicine","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Rebel Medicine \/ Crocker Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Rebel Medicine \/ Crocker Ventures"},{"orgOrder":0,"company":"Neuroversion","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Immunology","graph2":"Phase I","graph3":"Neuroversion","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Neuroversion \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Neuroversion \/ Undisclosed"},{"orgOrder":0,"company":"Yannis Raftopoulos","sponsor":"Heron Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Phase IV","graph3":"Yannis Raftopoulos","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Yannis Raftopoulos \/ Heron Therapeutics","highestDevelopmentStatusID":"11","companyTruncated":"Yannis Raftopoulos \/ Heron Therapeutics"},{"orgOrder":0,"company":"Ryan Mountjoy, MD","sponsor":"MaineHealth","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Neurology","graph2":"Phase IV","graph3":"Ryan Mountjoy, MD","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ryan Mountjoy, MD \/ MaineHealth","highestDevelopmentStatusID":"11","companyTruncated":"Ryan Mountjoy, MD \/ MaineHealth"},{"orgOrder":0,"company":"Endeavor Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Urology","country":"","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Urology","graph2":"Phase IV","graph3":"Endeavor Health","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Urology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Endeavor Health \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Endeavor Health \/ Undisclosed"},{"orgOrder":0,"company":"Casey Stondell","sponsor":"Pacira BioSciences","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Casey Stondell","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Casey Stondell \/ Pacira BioSciences","highestDevelopmentStatusID":"11","companyTruncated":"Casey Stondell \/ Pacira BioSciences"},{"orgOrder":0,"company":"Johnny K. Lee","sponsor":"Endeavor Health","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Johnny K. Lee","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnny K. Lee \/ Endeavor Health","highestDevelopmentStatusID":"11","companyTruncated":"Johnny K. Lee \/ Endeavor Health"},{"orgOrder":0,"company":"Northwestern University","sponsor":"Pacira BioSciences","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Undisclosed","graph2":"Phase III","graph3":"Northwestern University","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Northwestern University \/ Pacira BioSciences","highestDevelopmentStatusID":"10","companyTruncated":"Northwestern University \/ Pacira BioSciences"},{"orgOrder":0,"company":"Norton Healthcare","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Bupivacaine","moa":"Sodium channel protein type IV alpha subunit","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Norton Healthcare","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Norton Healthcare \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Norton Healthcare \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for (+-)-Bupivacaine

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : Bupivacaine

                          Therapeutic Area : Neurology

                          Study Phase : Phase II

                          Sponsor : Allay Therapeutics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : ATX-101 is a small product placed directly into the TKA surgical site in a simple, ‘place & go’ manner designed to add minimal extra complexity and time to the procedure.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 13, 2022

                          Lead Product(s) : Bupivacaine

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Allay Therapeutics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Evonik company banner

                          02

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : The proceeds will fund a Phase 2 clinical trial in bunionectomy patients to assess the safety and efficacy of Alevatrix, a novel, long‑acting formulation of bupivacaine for postoperative pain.

                          Product Name : Alevatrix

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          June 12, 2025

                          Lead Product(s) : Bupivacaine

                          Therapeutic Area : Neurology

                          Highest Development Status : IND Enabling

                          Sponsor : Crocker Ventures

                          Deal Size : $6.0 million

                          Deal Type : Series A Financing

                          blank

                          03

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : The proceeds will be used to advance ATX101, a novel investigational configuration of an approved, well-characterized, validated intracellular sodium ion channel blocker, bupivacaine.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Undisclosed

                          June 05, 2025

                          Lead Product(s) : Bupivacaine

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Lightstone Ventures

                          Deal Size : $57.5 million

                          Deal Type : Series D Financing

                          blank

                          04

                          University of California, San Diego

                          Country arrow
                          PREP
                          Not Confirmed

                          University of California, San Diego

                          Country arrow
                          PREP
                          Not Confirmed

                          Details : Bupivacaine is a Other Small Molecule drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of unspecified medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 29, 2025

                          Lead Product(s) : Bupivacaine

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase IV

                          Sponsor : Pacira BioSciences

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Bupivacaine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Analgesia.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          May 01, 2025

                          Lead Product(s) : Bupivacaine

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          University of Tennessee

                          Country arrow
                          PREP
                          Not Confirmed

                          University of Tennessee

                          Country arrow
                          PREP
                          Not Confirmed

                          Details : Bupivacaine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Pain, Postoperative.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          April 13, 2025

                          Lead Product(s) : Bupivacaine

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase IV

                          Sponsor : Regional One Health

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Probudur (bupivacaine) is a sodium channel alpha subunit blocker, small molecule drug candidate, which is currently being evaluated for the treatment of post-operative pain.

                          Product Name : Probudur

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          March 18, 2025

                          Lead Product(s) : Bupivacaine

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : ATX101 is a novel validated intracellular sodium ion channel blocker, bupivacaine, and a biopolymer that has been designed to provide weeks of pain relief following total knee arthroplasty.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 18, 2025

                          Lead Product(s) : Bupivacaine

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          PREP
                          Not Confirmed
                          PREP
                          Not Confirmed

                          Details : Probudur (bupivacaine) is a sodium channel alpha subunit blocker, small molecule drug candidate, which is currently being evaluated for the treatment of post-operative pain.

                          Product Name : Probudur

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          February 13, 2025

                          Lead Product(s) : Bupivacaine

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          MediSys Health Network

                          Country arrow
                          PREP
                          Not Confirmed

                          MediSys Health Network

                          Country arrow
                          PREP
                          Not Confirmed

                          Details : Bupivacaine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          December 05, 2024

                          Lead Product(s) : Bupivacaine

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase IV

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank